Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) and Berna Biotech AG (Swiss Exchange: BBIN) announced today that Crucell holds more than 98% of all issued shares of Berna Biotech. Crucell has filed for the cancellation of the remaining minority held shares in exchange for the consideration offered in the public exchange offer. This step is in line with previous announcements and the goal of fully integrating the two companies. The procedure, which is governed by the Swiss Act on Stock Exchanges and Securities Trading, is expected to last several months. Berna Biotech plans to have its shares delisted from the SWX Swiss Exchange upon completion of the cancellation procedure.
